홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

Triphenylphosphine → 2-Oxo-N-(1,2,4-thiadiazol-5-yl)-3-((2-(2,2,2-trifluoroethyl)-1,2,3,4 tetrahydroisoquinolin-8-yl)methyl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide

HRID 920223
인쇄

반응식

HRID 920223 반응식
COC1C=C(OC)C=CC=1C[N:6]([C:20]1[S:24][N:23]=[CH:22][N:21]=1)[S:7]([C:10]1[CH:19]=[CH:18][C:13]2[NH:14][C:15](=[O:17])[O:16][C:12]=2[CH:11]=1)(=[O:9])=[O:8].[F:31][C:32]([F:47])([F:46])[CH2:33][N:34]1[CH2:43][CH2:42][C:41]2[C:36](=[C:37]([CH2:44]O)[CH:38]=[CH:39][CH:40]=2)[CH2:35]1.C1(P(C2C=CC=CC=2)C2C=CC=CC=2)C=CC=CC=1>C1COCC1>[O:17]=[C:15]1[N:14]([CH2:44][C:37]2[CH:38]=[CH:39][CH:40]=[C:41]3[C:36]=2[CH2:35][N:34]([CH2:33][C:32]([F:47])([F:31])[F:46])[CH2:43][CH2:42]3)[C:13]2[CH:18]=[CH:19][C:10]([S:7]([NH:6][C:20]3[S:24][N:23]=[CH:22][N:21]=3)(=[O:8])=[O:9])=[CH:11][C:12]=2[O:16]1
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

5

반응물 3

HCID 11776TriphenylphosphineHCID 89526014(2-(2,2,2-Trifluoroethyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)methanolHCID 89526027N-(2,4-dimethoxybenzyl)-2-oxo-N-(1,2,4-thiadiazol-5-yl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide

생성물 1

HCID 1176292832-Oxo-N-(1,2,4-thiadiazol-5-yl)-3-((2-(2,2,2-trifluoroethyl)-1,2,3,4 tetrahydroisoquinolin-8-yl)methyl)-2,3-dihydrobenzo[d]oxazole-6-sulfonamide

시약·촉매·용매 1

HCID 8028Tetrahydrofuran용매

실험 절차

A solution of 1-5 (16.5 mg, 0.037 mmol) and 7-5 (9.02 mg, 0.037 mmol) in THF (368 μl) at RT was treated with PS-bound triphenylphosphine (1.84 mmol/g, 40.2 mg, 0.074 mmol), and DTBAD (16.94 mg, 0.074 mmol). After 30 min, LCMS showed complete consumption of SM. Filtered through Celite and concentrated in vacuo. Dissolved in 245 uL DCM, 123 uL TFA and stirred at RT. After 30 min, diluted with 1 mL MeOH, filtered through Celite and washed with 1 mL MeOH. Concentrated in vacuo and purified by reverse-phase HPLC (C18 column, 5-70% 0.1% TFA/CH3CN:0.1% TFA/H2O) to give 7-6 as an off-white solid. 1H NMR δ (ppm) (DMSO-d6): 8.48 (1H, s), 7.78 (1H, d, J=1.69 Hz), 7.67 (1H, dd, J=8.28, 1.72 Hz), 7.25 (1H, d, J=8.33 Hz), 7.14-7.09 (2H, m), 6.92 (1H, d, J=6.83 Hz), 5.00 (2H, s), 3.99 (3H, s), 3.54 (3H, d, J=12.20 Hz), 2.90 (2H, s). HRMS C21H19F3N5O4S2 [M+H] calc 526.0825, obs. 526.0806.

후처리

  1. customconsumption of SM
  2. filtrationFiltered through Celite
  3. concentrationconcentrated in vacuo
  4. dissolutionDissolved in 245 uL DCM
  5. waitAfter 30 min
  6. additiondiluted with 1 mL MeOH
  7. filtrationfiltered through Celite
  8. washwashed with 1 mL MeOH
  9. concentrationConcentrated in vacuo
  10. custompurified by reverse-phase HPLC (C18 column, 5-70% 0.1% TFA/CH3CN:0.1% TFA/H2O)

출처 및 근거

ORD 기록
ord-c59ca463e4544dfc9c4ba55f2d32040a
출처 데이터셋
uspto-grants-2016_03
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US09273040B2

반응 노트

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트